胰高血糖素样肽-1受体显像定位诊断胰岛素瘤的研究进展  

Advances of glucagon-like peptide-1 receptor imaging for localization of insulinoma

作　　者：罗亚平[1,2] 潘青青 霍力[1,2] 李方 LUO YaPing;PAN QingQing;HUO Li;LI Fang(Department of Nuclear Medicine,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China;Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine,Beijing 10073,China)

机构地区：[1]中国医学科学院&北京协和医学院,北京协和医院核医学科,北京100730 [2]核医学分子靶向诊疗北京市重点实验室,北京100730

出　　处：《中国科学：生命科学》2021年第8期1072-1084,共13页Scientia Sinica(Vitae)

基　　金：国家自然科学基金(批准号:8150,1515);公益性行业科研专项(批准号:2014,02001)资助。

摘　　要：胰岛素瘤的诊断和手术治疗依赖于准确的影像学检查定位.以胰腺β细胞为靶点的胰高血糖素样肽-1受体(glucagon-like peptide-1 receptor,GLP-1 receptor)显像是近年来建立的定位诊断胰岛素瘤的核医学分子影像新技术,有很高的诊断敏感性和特异性.本综述回顾了GLP-1受体显像的建立和临床研究情况,并展望了该技术的应用和研究前景.The diagnosis and surgical treatment of insulinoma is dependent on accurate localization with imaging modalities.Glucagon-like peptide-1(GLP-1)receptor imaging that targets pancreaticβcells,was recently established for localization of insulinoma in patients with hyperinsulinemic hypoglycemia.It has proven to be a sensitive and specific method for preoperative localization of insulinoma.This review introduces the development,clinical research,and perspective of GLP-1 receptor imaging mainly in insulinoma.

关 键 词：胰岛素瘤 胰高血糖素样肽-1受体 EXENDIN-4 

分 类 号：R736.7[医药卫生—肿瘤]